SUMMARY This study was designed to test the hypothesis that there is a myopathic component in myasthenia gravis. Serum enzyme analyses and lactate and pyruvate assays were undertaken before and after exercise in order to detect possible leakage from defective muscle membrane. A patient and a control group were exercised under (1) aerobic conditions, (2) ischaemic conditions, and (3) aerobic conditions under the influence of edrophonium chloride. The patient group showed a higher resting level of lactate in the aerobic state than did the controls. In addition, the average change in SGOT values in the patient group after one minute of aerobic exercise under the influence of edrophonium chloride exceeded that of the control group. Both these findings suggest possible leakage of enzyme and metabolite from the myasthenic muscle due to a membrane defect and support the hypothesis that there may be a myopathic component in myasthenia gravis. However, the two groups showed no significant differences in CPK values, which are often elevated in primary muscle diseases.
Several possible causes of myasthenia gravis have been described (Herrmann, 1967) : (1) autoimmunity, in which the body develops antibodies against its own muscle; (2) the presence of a neuromuscular blocking agent at the postsynaptic membrane; (3) a defect in production of liberation of acetylcholine at the presynaptic membrane; and (4) a slow virus infection with long latency and low virulence.
The demonstration of muscle binding antibodies in the serum of some patients with myasthenia gravis by Strauss, Seegal, Hsu, Burkholder, Nastuk, and Osserman in 1960 has been confirmed in other laboratories, giving support to the concept of myasthenia gravis as an autoimmune disease (Downes, Greenwood, and Wray, 1966; Simpson, 1966b) . These antibodies have an affinity for the I-band in striated muscle (McFarlin, Engel, and Strauss, 1966 ) and it has not been possible to show any binding of antibodies at the myoneural junction (Strauss and Kemp, 1967) . This suggests that the hypothesis of a progressive failure in neuromuscular transmission as the cause of myasthenia gravis may not be correct and that the fault may be at other :sites in the neuromuscular complex (Dameshek, 1 Supported by a grant from the Myasthenia Gravis Association of Detroit, Michigan. Namba and Grob (1968) that serum and serum globulin from patients with myasthenia gravis do not inhibit neuromuscular transmission. In fact, this study attributes a protective rather than a harmful role to striation binding globulin. The presence of serum antibodies within the muscle fibre suggests that there may be a functional defect within the fibre. There has, however, been little experimental work designed to test this hypothesis.
1965). It has been shown by
It is possible that the presence of antibodies might alter or interfere with muscle fibre metabolism, which might produce alterations in the levels of serum enzymes obtained in venous blood from patients with myasthenia gravis. Hess (1965) has demonstrated a moderate decrease in phosphorylase activity in muscle obtained from patients with myasthenia gravis and Hess, MacDonald, Frederick, Jones, Neely, and Gross (1964) reported that creatine phosphokinase (CPK) levels were normal in this disease, although one of their patients showed a significant elevation of the enzyme in the serum. Simpson (1966a) studied the serum enzyme levels of glutamic pyruvic transaminase, glutamic oxalacetic transaminase, aldolase, and CPK. He found no significant elevation of these enzymes in the 22 myasthenic patients studied. We have been unable to trace further reports on serum enzyme levels in the American or European literature but a report of serum enzyme activity has appeared in the Russian literature. Perelman and Matlina (1957) have shown that serum of patients with myasthenia gravis depressed the process of phosphocreatine formation in rat muscle to a greater degree than the serum of healthy controls.
The measurement of serum enzyme levels in patients with myasthenia gravis would seem to be of value for two reasons: (1) abnormalities may reflect an interference with muscle metabolism which could only be interpreted as a fault arising within the muscle cell; and (2) In the final phase of the study the subject exercised one more time under aerobic conditions after the intravenous injection of 5 mg edrophonium chloride (Tensilon). The drug was administered 15 seconds after the resting sample (EO) was drawn and 15 seconds before work commenced. Another blood sample was drawn exactly one minute after exercise began (E1) ( Table 3) .
The blood samples obtained during these procedures were analysed for creatine phosphokinase (CPK), serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), lactic dehydrogenase (LDH), and aldolase. Lactate Lactate and pyruvate levels were not measured before and after ischaemic testing and before and after aerobic testing under the influence of edrophonium. The decision to eliminate these tests was based on the difficulty of assessing muscle bulk in a quantitative manner in patients and control groups. In general, the control group had much better muscle development than the myasthenic group and it was felt that this would result in misleading figures for pyruvate and lactate levels after exercise, particularly under ischaemic conditions.
RESULTS
The raw data and mean values for the three states tested-that is, (1) aerobic exercise, (2) ischaemic exercise, and (3) aerobic exercise under the influence of edrophonium chloride-are listed in Tables 1 to 3 respectively. These Tables  enable one to Table 4 is used to compare the average change and is summarized in Table 5 . For example, the in enzyme or metabolite level from the resting mean value of lactate in the aerobic resting state state (E0) to the state achieved after one minute in the patient group was compared with that in of exercise (E1). In the case of lactate, the the control group. Table 5 indicates that Eo for average change (E,-Eo) after one minute of lactate has a confidence level of 099-that is, in aerobic exercise in the patient group, was 14 1 990 % of estimations the aerobic resting level of mg% -that is, the average patient had a 14-1 lactate in the patient group will differ significantly mg/100 ml. increase in his lactate level after one from that in the control group due to factors minute of aerobic exercise. The average change other than chance. A comparison of the average in the control group was 12-2 mg/100 ml. differences between patient and control levels
In order to determine if the mean values in the after one minute of aerobic exercise (E1-Eo in patient group were statistically different from this case, the difference between the patient value (14-1 mg/100 ml.) and the control value (12.2 mg/100 ml.) is most likely due to chance. Table 5 shows a number of situations in which differences of mean values are likely to be influenced by factors other than chance. If a confidence level of 0 95 or greater is considered to be statistically significant, there are three situations which fulfilled this criterion: (1) lactate in the aerobic resting state (EO), (2) SGOT in the aerobic state under the influence of edrophonium chloride (E1-Eo), and (3) aldolase in the aerobic resting state (EO).
It has already been pointed out that the mean aerobic resting level of lactate in the patient group (12-6 mg/100 ml.) was greater than the control group (5.1 mg/100 ml.). This difference is significant at the 0-99 confidence level.
The average increase (E1-Eo) in the SGOT value for the patient group was 3-2 mu/ml. The control group's average increase was 0-2 mu/ml. (see Table 4 ). This difference is significant at the 0 95 confidence level. This indicates that more SGOT has passed from muscle into the serum in the patient group than in the control group.
In the case of aldolase, the mean aerobic resting level was less in the patient group (8 1 mu/ml.) than in the control group (11-0 mu/ml.) (see Table 1 ). This difference is significant at the 0-96 confidence level.
LDH showed a mean aerobic resting level of 64-6 mu/ml. for the patient group and 42-4 mu/ ml. for the control group. The difference between these levels is significant at the 0-92 confidence level.
None of the mean values for CPK, SGPT, and pyruvate differed significantly between the two groups tested.
It is important to point out that, although some statistically significant differences do exist between patient and control group mean values, almost all the subjects' values did fall within normal limits as established by the Calbiochem Stat-Pak used in this study (see Table 6 for the normal ranges of the enzymes and metabolites Rowland, Hoefer, and Aranow (1958) but has been somewhat obscured by the more recent concept that myasthenia gravis may be an autoimmune disease, first suggested by Simpson (1960) . However, the two hypotheses are not mutually exclusive, since myositis is common in myasthenia and may have autoimmune causation (Simpson, 1960) .
The presence of serum antibodies within the muscle fibre is consistent with the hypothesis that the disease is a primary muscular disorder. The higher resting level of lactate in the patient group as compared with the control group also supports this hypothesis, since elevated lactic acid values in blood have been reported in several muscular disorders including muscular dystrophy (Goto, Peters, and Reese, 1967) . Goto et al. (1967) measured fasting lactate levels in patients with myasthenia gravis and in several other neuromuscular diseases. This was followed by the measurement of lactate levels at 60 and 90 minutes after dextrose loading. The patient group in that study showed an average fasting lactate of 6-9 mg/100 ml. compared with the 12-6 mg/100 ml. reported here. However, the patient group in the study by Goto et al. (1967) contained two subjects. The control group of 27 subjects had an average fasting lactate level of 5-10 mg/100 ml. This is the same value obtained in the control group of this study.
In the present study, SGOT was the only enzyme that showed a statistically significant change in the blood level after exercise. The average change in SGOT during aerobic exercise under the influence of edrophonium chloride was greater in the patient group than in the control group. This is significant at the 0 95 confidence level. In addition, the mean value of SGOT in the patient group after one minute of exercise was greater than that of the control group (see Table 3 ). This is significant at the 0-87 confidence level. These data suggest that there is increased leakage of SGOT from muscle in the patient group as compared with the control group. Serum aldolase levels are frequently elevated in patients with primary disease of muscle. In this study, the control group had a higher mean aerobic resting value of aldolase than the patient group. Sibley and Fleisher (1954) Tables 1, 2 , 3, patients R.S., and W.E.). This is consistent with the findings of Hess et al. (1964) who reported one myasthenic patient with an abnormal elevation of this enzyme in the serum.
SUMMARY
The enzyme levels of CPK, SGOT, SGPT, LDH, and aldolase were measured before and after exercise in patients with myasthenia gravis and in a control group. Lactate and pyruvate were also measured before and after exercise in the two groups. Both groups exercised for one minute by squeezing a sphygmomanometer bulb at the rate of one squeeze per second. Both groups exercised under (1) aerobic conditions, (2) ischaemic conditions, and (3) aerobic conditions after the injection of edrophonium chloride. The patient group showed a significantly higher resting level of lactate in the aerobic state than did the controls. In addition, the average change in SGOT values in the patient group after one minute of aerobic exercise under the influence of edrophonium chloride exceeded that of the control group. These findings suggest a possible leakage from myasthenic muscle due to a membrane defect and support the hypothesis that there is a myopathic component in myasthenia gravis. However, CPK values, which are often elevated in primary myopathies, were similar in both patient and control groups.
The nature of the pathology in myasthenia gravis is obscure. Some evidence has been presented here in favour of a primary muscle disorder. It is hoped that additional work in this area will clarify the nature of this disease which has eluded satisfactory explanation to date.
